<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411136</url>
  </required_header>
  <id_info>
    <org_study_id>20040250</org_study_id>
    <nct_id>NCT02411136</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Multi-dose Administration in Subjects With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety of AMG 623 in subjects with systemic lupus
      erythematosus. All subjects will receive 4 weekly doses of study drug over a 3 week period,
      and then will be followed for an additional 28 weeks, for total study duration of 31 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>up to 31 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant vital signs</measure>
    <time_frame>up to 31 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results</measure>
    <time_frame>up to 31 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant ECG results</measure>
    <time_frame>up to 31 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of AMG 623 including Tmax, AUClast and Cmax</measure>
    <time_frame>up to 31 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>AMG 623</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of AMG 623 administered as subcutaneous and intravenous doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of AMG 623 administered as subcutaneous and intravenous doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 623</intervention_name>
    <description>Multiple doses of AMG 623 administered as subcutaneous and intravenous doses</description>
    <arm_group_label>AMG 623</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple doses of AMG 623 administered as subcutaneous and intravenous doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between the ages of 18 and 65 years old

          -  Diagnosis of SLE

          -  Stable disease; defined as no change in SLE therapy within the previous 30 days. Up to
             5 mg/day incremental changes of prednisone therapy is allowed during the 30 days prior
             to randomization

          -  SLE disease duration of at least 1 year, as diagnosed by a physician

        Exclusion Criteria:

          -  Current renal disease

          -  Signs or symptoms of viral or bacterial infection within 30 days of enrollment

          -  Any disorder (including psychiatric), condition or clinically significant disease
             (other than a diagnosis of SLE) that would interfere the study evaluation, completion
             and/or procedures per the investigator's discretion

          -  Administration of more than 10 mg/day prednison (or equivalent) in the 30 days prior
             to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

